• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence.丙型肝炎病毒感染的直接抗病毒药物治疗与肝癌复发之间的可能关联。
Gastroenterol Hepatol (N Y). 2016 Dec;12(12):776-779.
2
Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.预测 HCV 感染 DAA 治疗后 HCC 的极早期发生。
Hepatol Int. 2018 Nov;12(6):523-530. doi: 10.1007/s12072-018-9895-5. Epub 2018 Sep 21.
3
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.直接作用抗病毒治疗与多中心北美队列研究中肝细胞癌的复发无关。
Gastroenterology. 2019 May;156(6):1683-1692.e1. doi: 10.1053/j.gastro.2019.01.027. Epub 2019 Jan 18.
4
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化中肝细胞癌的早期发生和复发。
J Hepatol. 2016 Oct;65(4):727-733. doi: 10.1016/j.jhep.2016.06.015. Epub 2016 Jun 24.
5
Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy?直接作用抗病毒治疗的肝移植患者肝细胞癌复发风险是否增加？
Hepatol Int. 2019 Mar;13(2):190-198. doi: 10.1007/s12072-019-09930-x. Epub 2019 Jan 24.
6
Increased recurrence rates of hepatocellular carcinoma after DAA therapy in a hepatitis C-infected Egyptian cohort: A comparative analysis.丙型肝炎感染的埃及队列中直接抗病毒药物（DAA）治疗后肝细胞癌复发率增加：一项比较分析。
J Viral Hepat. 2018 Jun;25(6):623-630. doi: 10.1111/jvh.12854. Epub 2018 Jan 24.
7
Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals.接受直接抗病毒药物治疗的丙型肝炎病毒患者肝细胞癌发生和复发的危险因素
Biomedicines. 2020 Jun 25;8(6):175. doi: 10.3390/biomedicines8060175.
8
HCV Eradication with Direct-Acting Antivirals Does Not Impact HCC Progression on the Waiting List or HCC Recurrence after Liver Transplantation.直接作用抗病毒药物清除 HCV 不会影响等待肝移植患者的 HCC 进展或移植后 HCC 复发。
Can J Gastroenterol Hepatol. 2019 Jan 17;2019:2509059. doi: 10.1155/2019/2509059. eCollection 2019.
9
Hepatocellular carcinoma after sustained virological response with interferon-free regimens in HIV/hepatitis C virus-coinfected patients.HIV/丙型肝炎病毒合并感染患者应用无干扰素方案获得持续病毒学应答后发生肝细胞癌。
AIDS. 2018 Jul 17;32(11):1423-1430. doi: 10.1097/QAD.0000000000001809.
10
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.直接作用抗病毒药物不会增加局部区域治疗或肝移植候补名单退出后肝细胞癌复发的风险。
Hepatology. 2018 Aug;68(2):449-461. doi: 10.1002/hep.29855. Epub 2018 May 16.

引用本文的文献

1
Five-Year Prospective Follow-Up of Patients with Hepatitis C Virus Infection Treated with Direct-Acting Antiviral Agents.接受直接抗病毒药物治疗的丙型肝炎病毒感染患者的五年前瞻性随访
Infect Drug Resist. 2025 Jan 24;18:455-471. doi: 10.2147/IDR.S487414. eCollection 2025.
2
Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon.炎症反应在肝细胞癌发病机制和治疗中的作用：一把双刃剑。
Int J Mol Sci. 2024 Jun 29;25(13):7191. doi: 10.3390/ijms25137191.
3
Frequency of Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up.慢性丙型肝炎直接抗病毒治疗后肝细胞癌的发生率：一项前瞻性随访研究
Euroasian J Hepatogastroenterol. 2022 Jul-Dec;12(2):73-76. doi: 10.5005/jp-journals-10018-1383.
4
Seven gene signature explores the impact of DAAs on the appearance of hepatocellular carcinoma in HCV infected patients.七基因特征研究直接抗病毒药物对丙型肝炎病毒感染患者肝细胞癌发生的影响。
Heliyon. 2022 Aug 8;8(8):e10119. doi: 10.1016/j.heliyon.2022.e10119. eCollection 2022 Aug.
5
Biomarkers for the Detection and Management of Hepatocellular Carcinoma in Patients Treated with Direct-Acting Antivirals.用于接受直接抗病毒药物治疗的肝细胞癌患者检测和管理的生物标志物
Cancers (Basel). 2022 May 30;14(11):2700. doi: 10.3390/cancers14112700.
6
Direct antiviral agents for HCV infection and hepatocellular carcinoma: facts and FADs.用于丙型肝炎病毒感染和肝细胞癌的直接抗病毒药物：事实与谬误。
Transl Cancer Res. 2019 Apr;8(Suppl 3):S223-S232. doi: 10.21037/tcr.2019.04.01.
7
Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients.丙型肝炎直接抗病毒治疗后肝细胞癌的肿瘤特征：与未接受抗病毒治疗患者的对比分析
World J Hepatol. 2021 Nov 27;13(11):1743-1752. doi: 10.4254/wjh.v13.i11.1743.
8
Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma.病毒相关慢性炎症在肝细胞癌发生发展中的作用及癌症免疫抑制机制
Cancers (Basel). 2021 Aug 30;13(17):4387. doi: 10.3390/cancers13174387.
9
Correlation between IL28B/TLR4 genetic variants and HCC development with/without DAAs treatment in chronic HCV patients.慢性丙型肝炎患者中IL28B/TLR4基因变异与接受或未接受直接抗病毒药物（DAA）治疗的肝细胞癌发生之间的相关性。
Genes Dis. 2019 May 27;7(3):392-400. doi: 10.1016/j.gendis.2019.05.004. eCollection 2020 Sep.
10
Incidence and risk factors of early HCC occurrence in HCV patients treated with direct acting antivirals: a prospective multicentre study.直接作用抗病毒药物治疗的 HCV 患者中 HCC 早期发生的发生率和风险因素：一项前瞻性多中心研究。
J Transl Med. 2019 Aug 28;17(1):292. doi: 10.1186/s12967-019-2033-x.

本文引用的文献

1
Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution.肝细胞癌与直接作用抗病毒治疗：变革后的争议
J Hepatol. 2016 Oct;65(4):663-665. doi: 10.1016/j.jhep.2016.07.004. Epub 2016 Jul 12.
2
Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma.丙型肝炎相关肝细胞癌肝移植术后的直接抗病毒治疗与肿瘤复发
J Hepatol. 2016 Oct;65(4):859-860. doi: 10.1016/j.jhep.2016.06.023. Epub 2016 Jul 5.
3
Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts.直接作用抗病毒药物对肝细胞癌复发影响的证据不足：来自三个法国国家研究署队列的数据。
J Hepatol. 2016 Oct;65(4):734-740. doi: 10.1016/j.jhep.2016.05.045. Epub 2016 Jun 7.
4
Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.接受无干扰素治疗的丙型肝炎相关 HCC 患者早期肿瘤复发率高。
J Hepatol. 2016 Oct;65(4):719-726. doi: 10.1016/j.jhep.2016.04.008. Epub 2016 Apr 13.

The Possible Association Between DAA Treatment for HCV Infection and HCC Recurrence.

作者信息

Robert S Brown

机构信息

Gladys and Roland Harriman Professor of Medicine Clinical Chief, Division of Gastroenterology and Hepatology Weill Cornell Medicine New York, New York.

出版信息

Gastroenterol Hepatol (N Y). 2016 Dec;12(12):776-779.

PMID:28035203
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5193084/
Abstract
摘要